Oncology Central

Vistusertib with paclitaxel shows promise for ovarian and lung cancer in early trial

In this study, researchers from the Institute of Cancer Research and The Royal Marsden (both London, UK), along with teams at nine other centres across the UK, tested a combination of vistusertib with paclitaxel chemotherapy on 25 women with high-grade, serous ovarian cancer and 40 patients with squamous non-small cell lung cancer.
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.